Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.62 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4537488 | 0.93 | TLR7 (0.61) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL14758154 | 0.83 | TLR7 (0.69) | TLR7TLR8 | |
| SCHEMBL4531131 | 0.81 | TLR7 (0.72) | TLR7TLR8NUDT1 | |
| SCHEMBL4520850 | 0.81 | TLR7 (0.62) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL4530116 | 0.78 | TLR7 (0.65) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL4531190 | 0.78 | TLR7 (0.71) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL29508382 | 0.78 | TLR7 (1.00) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL189202 | 0.78 | TLR7 (1.00) | TLR7TLR8NUDT1LMNAPOLB | |
| SCHEMBL4530112 | 0.78 | TLR7 (0.68) | TLR7TLR8NUDT1 | |
| SCHEMBL4520842 | 0.76 | TLR7 (0.58) | TLR7TLR8NUDT1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658666-B2 | Substituted imidazoquinolines and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-02-25 | — | — | US | disclosed |
| US-20090099161-A1 | Substituted Imidazoquinolines and Imidazonaphthyridines | COLEY PHARMACEUTIAL GROUP, INC. (NY) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099161-A1 | Substituted Imidazoquinolines and Imidazonaphthyridines | IL2, EIF2AK2, IFNG | TLR7 35/4885TLR8 90/4885NUDT1 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.